A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

CompletedOBSERVATIONAL
Enrollment

3,050

Participants

Timeline

Start Date

June 14, 2013

Primary Completion Date

November 21, 2018

Study Completion Date

November 21, 2018

Conditions
Prostate Cancer
Trial Locations (146)

Unknown

Salzburg

Vienna

Aalst

Antwerp

Bonheiden

Brasschaat

Bruges

Edegem

Ghent

Kortrijk

Liège

Ostend

Ottignies

Roeselare

Turnhout

Angers

Avignon

Béziers

Brest

Gap

Hyères

La Tronche

Marseille

Metz

Montpellier

Nancy

Paris

Périgueux

Pierre-Bénite

Pringy

Reims

Rennes

Saint-Grégoire

Saint-Mandé

Saint-Quentin

Toulouse

Tours

Augsburg

Bad Saarow

Bautzen

Berlin

Braunschweig

Chemnitz

Duisburg

Erkrath

Frankfurt

Hamburg

Holzminden

Jena

Kiel

Kirchheim

Nürtingen

Remscheid

Reutlingen

Rostock

Schwerin

Sindelfingen

Tübingen

Ulm

Weiden

Wilhelmshaven

Würselen

Beer Yaakov

Beersheba

Haifa

Holon

Tel Aviv

Luxembourg

Niedercorn

Bydgoszcz

Gdynia

Krakow

Lodz

Opole

Poznañ

Warsaw

Braga

Coimbra

Evora

Lisbon

Porto

Setúbal

Moscow

Obninsk

Omsk

Rostov-on-Don

Saint Petersburg

Ufa

Yekaterinburg

Celje

Ljubljana

Slovenj Gradec

A Coruña

Asturias

Barakaldo Vizcaya

Barcelona

Bilbao Vizcaya

Girona

Langreo

Palma de Mallorca

Pontevedra

Sabadell

Salamanca

Santiago de Compostela

Valladolid

Zaragoza

Borås

Gothenburg

Malmo

Örebro

Östersund

Stockholm

Umeå

Vaxjo

Västerås

Aarau

Winterthur

Ankara

Edirne

Istanbul

Izmir

Kayseri

Kocaeli

Turkey

Ashton-under-Lyne

Barnstaple

Blackburn

Bournemouth

Bradford

Brighton Sussex

Burton

Crewe

Huddersfield

Lancaster

Leeds Yorks

London

N/a N/a

Plymouth

Scunthorpe

Steeton

Stoke-on-Trent

Taunton

Torquay

Wakefield

Wigan

York

All Listed Sponsors
lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

NCT02236637 - A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care | Biotech Hunter | Biotech Hunter